Abstract

Aims The aim of the present analysis was to estimate the cost-effectiveness of intense insulin treatment after acute myocardial infarction in patients with diabetes mellitus based on the results of the Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. In this study 620 patients with diabetes mellitus and acute myocardial infarction were randomized to intense insulin treatment (insulin group) or to serve as controls given standard antidiabetic therapy. Mortality was significantly reduced in the insulin group.

Methods and Results The cost-effectiveness ratio was estimated as the incremental cost per life-year and quality-adjusted life-year gained of intense insulin treatment. The incremental costs were estimated as the difference in health care costs and indirect costs (labour production) during the first year of follow-up plus the future costs of increased survival. The life-years gained were based on the 5-year long-term follow-up experience and an assumed annual 20% mortality risk for all patients thereafter. The health care costs were Euro 975 higher in the insulin group during the first year of follow-up, mainly due to a longer period of initial hospitalization related to the institution of multidose insulin. The estimated discounted gain in life-years of the insulin treatment was 0·94 years without and 0·66 with quality of life adjustment, respectively. The cost per life-year gained by intense insulin treatment was Euro 16900 and the cost per quality-adjusted life-year gained was Euro 24100. Thus the estimated cost-effectiveness ratios were relatively low.

Conclusion The results of the DIGAMI study indicate that intense insulin treatment after an acute myocardial infarction in patients with diabetes mellitus has an acceptable level of cost-effectiveness.

f1
Correspondence: Björn Almbrand, MD, Department of Cardiology, Karolinska Hospital, S-171 76 Stockholm, Sweden.

References

1
Malmberg
K
, Rydén L. Myocardial infarction in patients with diabetes mellitus.
Eur Heart J
 .
1988
;
9
:
256
–264
2
Stone
P
, Muller J, Hartwell T. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis.
J Am Coll Cardiol
 .
1989
;
14
:
49
–57
3
Karlson
BW
, Herlitz J, Hjalmarson A. Prognosis of acute myocardial infarction in diabetic and non-diabetic patients.
Diabet Med
 .
1993
;
10
:
449
–454
4
Barbash
GI
, White HD, Modan M, Van dWerff F. Significance of diabetes mellitus in patients with acute myocardial infarction receiving thrombolytic therapy.
J Am Coll Cardiol
 .
1993
;
22
:
707
–713
5
Malmberg
K
, Rydén L, Efendic S. A randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year.
J Am Coll Cardiol
 .
1995
;
26
:
57
–65
6
Malmberg
K
. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus.
Br Med J
 .
1997
;
314
:
1512
–1515
7
Drummond
MF
, O'Brien B, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes, second edition. Oxford: Oxford Medical Publications; 1997.
8
Johannesson
M
. Theory and methods of economic evaluation of health care. Dordrecht: Kluwer Academic Publishers; 1996.
9
Meltzer
D
. Accounting for future costs in medical cost-effectiveness analysis.
J Health Econ
 .
1997
;
16
:
33
–64
10
Johannesson
M
, Meltzer D, O'Conor RM. Incorporating future costs in medical cost-effectiveness analysis: implications for the cost-effectiveness of the treatment of hypertension.
Med Decis Making
 .
1997
;
17
:
382
–389
11
Johannesson
M
, Meltzer D. Some reflections on cost-effectiveness analysis.
Health Economics
 .
1998
;
7
:
1
–7
12
Weinstein
MC
, Siegel JE, Gold MR, Kamlet MS, Russel LB. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine.
JAMA
 .
1996
;
276
:
1253
–1258
13
Läkemedelsinformation
AB
. FASS 1998, Pharmaceutical specialities in Sweden. Stockholm: Läkemedelsinformation AB; 1998.
14
Statistical yearbook of Sweden. Stockholm: Statistics Sweden; 1998.
15
Beck
JR
, Kassirer JP, Pauker SG. A convenient approximation of life expectancy (the “DEALE”): I. Validation of the method.
Am J Med
 .
1982
;
73
:
883
–888
16
Beck
JR
, Kassirer JP, Pauker SG. A convenient approximation of life expectancy (the “DEALE”): II. Use in medical decision-making.
Am J Med
 .
1982
;
73
:
889
–897
17
Lundberg
L
, Johannesson M, Isacson DGL, Borgquist L. Health-state utilities in a general population in relation to age, gender, and socioeconomic factors.
Eur J Public Health
 .
1999
;
9
:
211
–217
18
Tsevat
J
, Goldman L, Soukup JR, Lamas GA, Connors KF, Chapin CC, Lee TH. Stability of time-tradeoff utilities in survivors of myocardial infarction.
Med Decis Making
 .
1993
;
13
:
161
–165
19
Glasziou
PP
, Bromwich S, Simes JR. Quality of life six months after myocardial infarction treated with thrombolytic therapy.
Med J Australia
 .
1994
;
161
:
532
–536
20
Newbold
P
. Statistics for business and economics. Englewood Cliffs: Prentice-Hall; 1991.
21
SAMPLAN, Översyn av samhällsekonomiska kalkylvärden för den nationella trafikplaneringen 1994–1998, Stockholm, SAMPLAN, 1995
22
Laupacis
A
, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations.
Can Med Assoc J
 .
1992
;
146
:
473
–481
23
Martens
LL
, Rutten FF, Erkelens DW, Ascoop CA. Cost-effectiveness of cholesterol-lowering therapy in the Netherlands.
Am J Med
 .
1989
;
87
:
54S
–58S
24
Tosteson
AN
, Rosenthal DI, Melton LJ, Weinstein MC. Cost-effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy.
Ann Int Med
 .
1990
;
113
:
594
–603
25
Goldman
L
, Weinstein MC, Goldman PA, Williams LW. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease.
JAMA
 .
1991
;
265
:
1145
–1151
26
van Hout
B
, Bonsel G, Habbema D, Vandermaas P, Decharro F. Heart transplantation in the Netherlands: costs, effects and scenarios.
J Health Econ
 .
1993
;
12
:
73
–93
27
Johannesson
M
, Borgquist L, Jönsson B, Lindholm LH. The cost effectiveness of lipid lowering in Swedish primary health care.
J Intern Med
 .
1996
;
240
:
23
–29
28
Johannesson
M
, Jönsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost-effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease.
N Engl J Med
 .
1997
;
336
:
332
–336

Comments

0 Comments